Uncategorized
Ophthotech reaches $50 million enrollment milestone goal for Fovista phase 3 trial
Ophthotech has achieved a second $50 million enrollment milestone goal for Fovista under its ex-U.S. licensing and commercialization agreement with Novartis, according to a press release.Fovista, an anti-PDGF compound, is being combined with anti-VEGF therapy for the treatment of wet age-related macular degeneration in a phase 3 clinical program.